Jakub Zimodro

Mr. Jakub Zimodro


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JZJakub Zimodro
Jakub Zimodro
MANFREDI RIZZOMANFREDI RIZZO
MANFREDI RIZZO
Ioanna Gouni-BertholdIoanna Gouni-Berthold
Ioanna Gouni-Berthold
Hypertriglyceridemia (HTG) is associated with a residual risk of atherosclerotic cardiovascular disease. Extremely elevated triglyceride (TG) concentrations, particularly due to familial chylomicronemia syndrome (FCS), pose a risk for acute pancreatitis. Standard therapies with statins, fibrates, omega-3 fatty acids, and niacin may be insufficient to reduce elevated TG levels and improve clinical outcomes in patients with HTG. Novel antisense oligonucleotides and small interfering ribonucleic acids target the key modulators of TG-rich lipoprotein catabolism. Among apolipoprotein C-III (apoC-III) inhibitors, olezarsen and plozasiran appear to be safer alternatives for volanesorsen regarding the risk of drug-induced thrombocytopenia in patients with FCS or severe HTG. After the failure of vupanorsen, a new angiopoietin-like protein 3 (ANGPTL3) inhibitor, zodasiran, demonstrated the potential to decrease TG levels in patients with moderate HTG. Meanwhile, the fibroblast growth factor 21 (FGF21) analog, pegozafermin, became another candidate for the treatment of severe HTG. This comprehensive review outlines pharmacological targets in TG-rich lipoprotein metabolism, discusses international guidelines, and summarizes the latest evidence from clinical trials to provide insight into the current and emerging treatment options for primary HTG.

9 July 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JZJakub Zimodro
Jakub Zimodro
MMMagda Mucha
Magda Mucha
HBHeiner K. Berthold
Heiner K. Berthold
Ioanna Gouni-BertholdIoanna Gouni-Berthold
Ioanna Gouni-Berthold
Lipid-lowering therapy (LLT) is a cornerstone of atherosclerotic cardiovascular disease prevention. Although LLT might lead to different reductions in low-density lipoprotein cholesterol (LDL-C) levels in women and men, LLT diminishes cardiovascular risk equally effectively in both sexes. Despite similar LLT efficacy, the use of high-intensity statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors is lower in women compared to men. Women achieve the guideline-recommended LDL-C levels less often than men. Greater cholesterol burden is particularly prominent in women with familial hypercholesterolemia. In clinical practice, women and men with dyslipidemia present with different cardiovascular risk profiles and disease manifestations. The concentrations of LDL-C, lipoprotein(a), and other blood lipids differ between women and men over a lifetime. Dissimilar levels of LLT target molecules partially result from sex-specific hormonal and genetic determinants of lipoprotein metabolism. Hence, to evaluate a potential need for sex-specific LLT, this comprehensive review (i) describes the impact of sex on lipoprotein metabolism and lipid profile, (ii) highlights sex differences in cardiovascular risk among patients with dyslipidemia, (iii) presents recent, up-to-date clinical trial and real-world data on LLT efficacy and safety in women, and (iv) discusses the diverse medical needs of women and men with dyslipidemia and increased cardiovascular risk.

3 May 2024 in Archives of Medical Science
Verified
Journal Article
Open access
JZJakub Zimodro
Jakub Zimodro
Aleksandra GąseckaAleksandra Gąsecka
Aleksandra Gąsecka
PAPiotr Arski
Piotr Arski
JSJonas Schwarz
Jonas Schwarz
Maciej BanachMaciej Banach
Maciej Banach
Ioanna Gouni-BertholdIoanna Gouni-Berthold
Ioanna Gouni-Berthold

20 October 2025 in Archives of Medical Science
Verified
Journal Article
Open access
TSTomasz Saniewski
Tomasz Saniewski
JZJakub Zimodro
Jakub Zimodro
Grzegorz ProcykGrzegorz Procyk
Grzegorz Procyk
OWOlivia Wasilewska
Olivia Wasilewska
BMBartosz Mroczyk
Bartosz Mroczyk
Aleksandra GąseckaAleksandra Gąsecka
Aleksandra Gąsecka
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in Poland. Lipoprotein (a) [Lp(a)] constitutes an independent, causal risk factor for ASCVD and aortic valve stenosis. Elevated Lp(a) is found in approximately 20% of the Polish population. Lp(a) measurements have been recommended in all adult patients to improve cardiovascular risk stratification. As the testing rate remains insufficient, there is a need to facilitate the incorporation of Lp(a) into routine patient care. This clinically oriented review outlines (i) up-to-date evidence on the role of Lp(a) in cardiovascular diseases, (ii) recent real-world data on the characteristics of Polish patients with elevated Lp(a), and (iii) strategies for Lp(a) testing and management in light of the current national recommendations and the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidemias.

22 June 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
JZJakub Zimodro
Jakub Zimodro
MMMagda Mucha
Magda Mucha
HBHeiner K. Berthold
Heiner K. Berthold
Ioanna Gouni-BertholdIoanna Gouni-Berthold
Ioanna Gouni-Berthold
Lipid-lowering therapy (LLT) is a cornerstone of atherosclerotic cardiovascular disease prevention. Although LLT might lead to different reductions in low-density lipoprotein cholesterol (LDL-C) levels in women and men, LLT diminishes cardiovascular risk equally effectively in both sexes. Despite similar LLT efficacy, the use of high-intensity statin, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors is lower in women compared to men. Women achieve the guideline-recommended LDL-C levels less often than men. Greater cholesterol burden is particularly prominent in women with familial hypercholesterolemia. In clinical practice, women and men with dyslipidemia present with different cardiovascular risk profiles and disease manifestations. The concentrations of LDL-C, lipoprotein(a) and other blood lipids differ between women and men over a lifetime. Dissimilar levels of LLT’s target molecules partially result from sex-specific hormonal and genetic determinants of lipoprotein metabolism. Hence, to evaluate a potential need for sex-specific LLT, this comprehensive review (i) describes the impact of sex on lipoprotein metabolism and lipid profile, (ii) highlights sex differences in cardiovascular risk among patients with dyslipidemia, (iii) presents recent, up-to-date clinical trial and real-world data on LLT efficacy and safety in women, and (iv) discusses diverse medical needs of women and men with dyslipidemia and increased cardiovascular risk.

29 September 2023 in Cardiology Journal
Verified
Journal Article
Open access
PDF file
Ewelina BłażejowskaEwelina Błażejowska
Ewelina Błażejowska
JZJakub Zimodro
Jakub Zimodro
TFTomasz Figatowski
Tomasz Figatowski
ABAdam Brzeski
Adam Brzeski
TDTomasz Dziubich
Tomasz Dziubich
RTRadoslaw Targonski
Radoslaw Targonski